NCT06040320 2026-05-27Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Washington University School of MedicinePhase 1/2 Recruiting12 enrolled